GMED
Price
$51.95
Change
+$1.48 (+2.93%)
Updated
May 3, 6:59 PM EST
4 days until earnings call
RSLS
Price
$0.17
Change
-$0.00 (-0.00%)
Updated
May 3, 6:59 PM EST
Ad is loading...

Compare trend and price GMED vs RSLS

Header iconGMED vs RSLS Comparison
Open Charts GMED vs RSLSBanner chart's image
Globus Medical
Price$51.95
Change+$1.48 (+2.93%)
Volume$338.43K
CapitalizationN/A
ReShape Lifesciences
Price$0.17
Change-$0.00 (-0.00%)
Volume$34.09K
CapitalizationN/A
View a ticker or compare two or three
GMED vs RSLS Comparison Chart

Loading...

GMEDDaily Signal changed days agoGain/Loss if shorted
 
Show more...
RSLSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
GMED vs. RSLS commentary
May 04, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GMED is a Hold and RSLS is a Hold.

COMPARISON
Comparison
May 04, 2024
Stock price -- (GMED: $50.48 vs. RSLS: $0.18)
Brand notoriety: GMED and RSLS are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: GMED: 73% vs. RSLS: 57%
Market capitalization -- GMED: $7.19B vs. RSLS: $4.33M
GMED [@Medical Specialties] is valued at $7.19B. RSLS’s [@Medical Specialties] market capitalization is $4.33M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $7.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GMED’s FA Score shows that 1 FA rating(s) are green whileRSLS’s FA Score has 1 green FA rating(s).

  • GMED’s FA Score: 1 green, 4 red.
  • RSLS’s FA Score: 1 green, 4 red.
According to our system of comparison, both GMED and RSLS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GMED’s TA Score shows that 2 TA indicator(s) are bullish while RSLS’s TA Score has 7 bullish TA indicator(s).

  • GMED’s TA Score: 2 bullish, 5 bearish.
  • RSLS’s TA Score: 7 bullish, 2 bearish.
According to our system of comparison, RSLS is a better buy in the short-term than GMED.

Price Growth

GMED (@Medical Specialties) experienced а +0.22% price change this week, while RSLS (@Medical Specialties) price change was -1.52% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +2.00%. For the same industry, the average monthly price growth was -2.87%, and the average quarterly price growth was +13.44%.

Reported Earning Dates

GMED is expected to report earnings on Aug 01, 2024.

RSLS is expected to report earnings on May 15, 2023.

Industries' Descriptions

@Medical Specialties (+2.00% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
A.I.dvisor published
a Summary for GMED with price predictions.
OPEN
A.I.dvisor published
a Summary for RSLS with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
GMED($7.19B) has a higher market cap than RSLS($4.33M). GMED YTD gains are higher at: -5.273 vs. RSLS (-29.796). GMED has higher annual earnings (EBITDA): 347M vs. RSLS (-36.72M). GMED has more cash in the bank: 518M vs. RSLS (1.45M). RSLS has less debt than GMED: RSLS (285K) vs GMED (520M). GMED has higher revenues than RSLS: GMED (1.57B) vs RSLS (9.81M).
GMEDRSLSGMED / RSLS
Capitalization7.19B4.33M166,289%
EBITDA347M-36.72M-945%
Gain YTD-5.273-29.79618%
P/E Ratio49.65N/A-
Revenue1.57B9.81M15,990%
Total Cash518M1.45M35,749%
Total Debt520M285K182,456%
FUNDAMENTALS RATINGS
GMED vs RSLS: Fundamental Ratings
GMED
RSLS
OUTLOOK RATING
1..100
1711
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
28
Undervalued
PROFIT vs RISK RATING
1..100
88100
SMR RATING
1..100
8699
PRICE GROWTH RATING
1..100
5865
P/E GROWTH RATING
1..100
22100
SEASONALITY SCORE
1..100
n/a95

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RSLS's Valuation (28) in the Medical Specialties industry is somewhat better than the same rating for GMED (78). This means that RSLS’s stock grew somewhat faster than GMED’s over the last 12 months.

GMED's Profit vs Risk Rating (88) in the Medical Specialties industry is in the same range as RSLS (100). This means that GMED’s stock grew similarly to RSLS’s over the last 12 months.

GMED's SMR Rating (86) in the Medical Specialties industry is in the same range as RSLS (99). This means that GMED’s stock grew similarly to RSLS’s over the last 12 months.

GMED's Price Growth Rating (58) in the Medical Specialties industry is in the same range as RSLS (65). This means that GMED’s stock grew similarly to RSLS’s over the last 12 months.

GMED's P/E Growth Rating (22) in the Medical Specialties industry is significantly better than the same rating for RSLS (100). This means that GMED’s stock grew significantly faster than RSLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GMEDRSLS
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bearish Trend 2 days ago
60%
Bullish Trend 2 days ago
88%
MACD
ODDS (%)
Bearish Trend 2 days ago
66%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
68%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
55%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
88%
Declines
ODDS (%)
Bearish Trend 15 days ago
57%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
51%
Bullish Trend 2 days ago
89%
View a ticker or compare two or three
Ad is loading...
GMEDDaily Signal changed days agoGain/Loss if shorted
 
Show more...
RSLSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KRMD2.380.13
+5.78%
KORU Medical Systems
BIO279.315.25
+1.92%
Bio-Rad Laboratories IncClass A
BKYI1.69-0.01
-0.59%
BIO-key International
SCWX5.90-0.18
-2.96%
SecureWorks Corp
PAX12.71-0.68
-5.08%
Patria Investments Limited

GMED and

Correlation & Price change

A.I.dvisor indicates that over the last year, GMED has been loosely correlated with IART. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if GMED jumps, then IART could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GMED
1D Price
Change %
GMED100%
+0.10%
IART - GMED
49%
Loosely correlated
-1.47%
IDXX - GMED
49%
Loosely correlated
+1.66%
KIDS - GMED
48%
Loosely correlated
+2.48%
ATEC - GMED
44%
Loosely correlated
+1.85%
TMO - GMED
44%
Loosely correlated
-0.65%
More